alexa Comparison of Two Formulations of Sodium Divalproate Pl
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Comparison of Two Formulations of Sodium Divalproate Plasma Concentrations after a Single 500 mg Oral Dose in Healthy Subjects, and Stochastic Sub-analysis of the Individual “ Clinical Perceptible ” Levels

Nunez DA*, Schiaffino S and Roldán EJA

Scientific Direction Gador SA, Buenos Aires, Argentina

*Corresponding Author:
Nunez DA
Scientific Direction Gador SA
Buenos Aires, Argentina
E-mail: [email protected]

Received Date: June 25, 2013; Accepted Date: August 28, 2013; Published Date: September 04, 2013

Citation: Nunez DA, Schiaffino S, Roldán EJA (2013) Comparison of Two Formulations of Sodium Divalproate Plasma Concentrations after a Single 500 mg Oral Dose in Healthy Subjects, and Stochastic Sub-analysis of the Individual “Clinical Perceptible” Levels. J Bioequiv Availab 5:197-200. doi: 10.4172/jbb.1000158

Copyright: © 2013 Nunez DA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



A new generic formula containing 500 mg of sodium divalproate in enteric releasing coated tablets was compared to the reference product in a pharmacokinetic, randomized, cross-over 2×2 study performed in 24 healthy adult males. After administering a single dose, it was demonstrated that the maximum plasma concentration of valproic acid varies within the 98.4-113.0 range for 90% CI (test/reference); and the area under the curve of plasma levels over the 24 h period following the intake varies within the 91.1-99.5 range; therefore, it can be seen that both parameters are within the range of acceptance for the interchangeability of the products. Individual results show the typical inter- subject and inter -treatment variations of divalproate. Since the latter have an impact on the prescription decision, results are sub-analyzed considering a plasma threshold of valproic acid as effective or stochastically clinical perceptible (Cper).Complete duration of plasma levels above Cper is comparable for both formulations (p<0.81); nevertheless, the test product reaches the Cper value faster than the reference compound (p<0.04). Therefore, we consider that the individual perception of efficacy of the generic product should not be inferior to that of the reference. In conclusion, the tested formula is bioequivalent and the further sub-analysis of individual variations above a plasma level of stochastic clinical perception of effects shows non-relevant differences between both brands.


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version